The Ministry of Industry has resolved the 2019 call for the ‘Profarma: Promotion of competitiveness in the Pharmaceutical Industry’ program, in which fifty-three applications have been evaluated, resulting in ten of them with the rating of ‘excellent’, six Spanish.
The program qualifies and classifies companies based on their excellence in industrial, economic and research, development and innovation aspects. The excellent ones are Novartis, Almirall, Esteve Pharmaceuticals, Glaxosmithkline, Grifols, Grupo Ferrer Internacional, Insud Pharma, Rovi, Lilly and PharmaMar.
Another seven have been rated as “very good”, and they are Boehringer Ingelheim Spain, Faes Farma, Janssen Cilag, Reig Jofre Laboratory, Salvat Laboratories, Servier Laboratories and Merck. As “good” are ALK Abelló, Bioiberica, GP-Pharm, Normon, Neuraxpharm Holdco Iberia, Pfizer and Tigenix.
In the “acceptable” category, Bayer, Celgene, Industrial Farmacéutica Cantabria, Italdrug, Kern Pharma, Cinfa Laboratories, Leti Laboratories, Menarini Laboratories, Viñas Laboratories, Merck Sharp & Dohme, Sanofi-Aventis and Roche Farma appear.
The Secretary General for Industry and SMEs, Raúl Blanco, expressed his satisfaction at the “success” of a program “whose objective is to favor the competitiveness of the sector, promoting activities that provide greater added value, such as investment in new plants and new production technologies, promoting R+D+i”.
The assessment of pharmaceutical companies in this ‘ranking’ brings with it a reduction in contributions to the National Health System. According to the qualifications of the 2019 call, a total of 36 companies will be able to benefit from these reductions.
Facebook Comments
Disqus